Pfizer lasofoxifene review extension
This article was originally published in Pharmaceutical Approvals Monthly
FDA extends its June 19 action date by three months for Pfizer's selective estrogen receptor modulator Oporia (lasofoxifene) for treatment of osteoporosis, Pfizer says July 20. Pfizer was "so thorough and provided so much data [in response to the agency's questions] that the FDA decided that this…constituted a new review cycle," Global R&D President John LaMattina told investors. Pfizer previously suggested that Oporia could have advantages over Lilly's market leading SERM Evista (raloxifene), reflected in parameters for bone resorption, bone mineral density and LDL cholesterol reduction (1Pharmaceutical Approvals Monthly October 2004, p. 25)...
You may also be interested in...
Pfizer/Ligand’s lasofoxifene could be the first approved "next-generation" selective estrogen receptor modulator for osteoporosis.
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.